Abstract:Background: Valve-in-valve transcatheter mitral valve replacement (ViV-TMVR) is a minimally invasive option for patients with bioprosthetic mitral valve failure. Since January 2019, our center has been using a new innovative option, J-Valve, to treat patients with bioprosthetic mitral valve failure who were at high risk for open heart surgery. The aim of this study is to explore the effectiveness and safety of J-Valve and report the results from the four-year follow-up period of the innovative application of the transcatheter valve. Methods: Patients who underwent the ViV-TMVR procedure between January 2019 and September 2022 in our center were included in the study. J-ValveTM system (JC Medical Inc., Suzhou, China) with three U-shape grippers was used for ViV-TMVR via transapical approach. Data on survival, complications, transthoracic echocardiographic results, New York Heart Association functional class in heart failure, and patient-reported health-related quality of life according to the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) were collected during the four-year follow up. Results: Thirty-three patients (mean age 70.1 ± 1.1 years, 13 men) were included and received ViV-TMVR. The surgery success rate was 97%: only one patient was converted to open-heart surgery due to intraoperative valve embolization to the left ventricle. During the first 30 days all-cause mortality was 0%, risk of stroke 2.5% and risk of mild paravalvular leak 15.2%; mitral valve hemodynamics improved (179.7 ± 8.9 at 30 days vs. 269 ± 49 cm/s at baseline, p < 0.0001). Median time from operation to discharge was six days, and there were no readmissions within 30 days from operation. The median and maximum follow-up durations were 28 and 47 months, respectively; during the entire follow-up, all-cause mortality was 6.1%, and the risk of cerebral infarction 6.1%. Cox regression analysis did not identify any variables significantly associated with survival. The New York Heart Association functional class and the KCCQ-12 score improved significantly compared with their preoperative values. Conclusion: The use of J-Valve for ViV-TMVR is safe and effective with a high success rate, low mortality and very few associated complications, representing an alternative surgical strategy for the elderly, high-risk patients with bioprosthetic mitral valve failure.

Benefits of On-X Mitral Valve Replacement in Cases of Infective Endocarditis

Mitral valve repair and replacement in infectious endocarditis: a systematic review and meta-analysis of clinical outcome

Outcome of patient undergoing redo mitral valve surgery with incidence rate of mitral valve infective endocarditis

Surgical Management of Severe Ischaemic Mitral Regurgitation

Infective endocarditis after surgical aortic or mitral valve replacement: A nationwide population-based study

Ischemic mitral regurgitation: To repair or replace? A single center experience

Effects of mitral valve disease etiology on the outcomes of mechanical and biological valve replacement: retrospective cohort study

Contraindicated or Safely Possible?

Survival And Recurrence Of Endocarditis Following Mechanical Vs. Biological Mitral Valve Replacement For Endocarditis In Patients Aged 40 To 70 Years: Data From The Infect-Registry

Safety and Effectiveness of Catheter Ablation of Atrial Fibrillation in Patients with Mitral Valve Replacement Mechanical Versus Bioprosthetic Valves

Tissue versus mechanical mitral valve replacement in patients aged 50-70: a propensity-matched analysis

Mechanical versus Biological Valve Prostheses for Infective Endocarditis Presenting with Stroke

Clinical outcomes following surgical mitral valve repair or replacement in patients with rheumatic heart disease: a meta-analysis

The Role of Microbes in Surgical Decision Making for Infective Endocarditis: Mitral Valve Repair or Replacement?

Treatment for Prosthetic Valve Endocarditis after Mitral Valve Replacement Therapy

Outcomes of Different Mitral Valve Approaches Combined with Aortic Valve Replacement in Patients with Degenerative Valve Disease

Impact of additive mitral valve surgery to coronary artery bypass grafting on mortality in patients with coronary artery disease and ischaemic mitral regurgitation: a systematic review and meta-analysis of randomized trials and observational studies

Patient and Surgeon Predictors of Mitral and Tricuspid Valve Repair for Infective Endocarditis

Innovative use of a self-expanding valve for valve-in-valve transcatheter mitral valve replacement: experience from a four-year single-center study

Mitral Valve Repair and Mitral Valve Replacement in the Treatment of Infective Endocarditis Mitral Valve Regurgitation in the Long-Term Curative Effect Comparison

Hemodynamic Comparison of the On-X and Top Hat Mechanical Aortic Valve Prostheses